Rupa Narayan, Ana Alfonso Piérola, William B Donnellan, Antonieta Molero Yordi, Maher Abdul-Hay, Uwe Platzbecker, Marion Subklewe, Tapan Mahendra Kadia, Juan Manuel Alonso-Domínguez, James McCloskey, Kathryn Bradford, Martin Curtis, Nikki Daskalakis, Christina Guttke, Karim Safer, Brett Hiebert, Joseph Murphy, Xiang Li, Ken Duchin, Daniel Esteban
Relapsed/refractory (r/r) acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) outcomes remain poor. A targeted cluster of differentiation (CD)33 × CD3 bispecific antibody, JNJ-67571244, was assessed to identify the maximum tolerated dose (MTD), recommended phase II dose (RP2D), safety and tolerability, and preliminary clinical activity in patients with r/rAML or r/rMDS. This first-in-human, open-label, phase I, dose-escalation/dose-expansion study included patients with r/rAML or r/rMDS who were ineligible for or had exhausted standard therapeutic options...
March 2024: Clinical and Translational Science